Hsin Yang Liu
Corporate Officer/Principal bei TSH BIOPHARM CORPORATION LIMITED
Profil
Hsin Yang Liu is currently the Vice General Manager-General Administration at TSH Biopharm Corp., Ltd.
Previously, she held the position of VP-Administrative, Director-Accounting & Finance at Body Organ Biomedical Corp.
in 2012.
She also served as a Member-Supervisory Board at Reber Genetics Co., Ltd.
Dr. Liu completed her undergraduate and graduate degrees at National Taiwan University and obtained a doctorate degree from Nankai University.
Aktive Positionen von Hsin Yang Liu
| Unternehmen | Position | Beginn |
|---|---|---|
| TSH BIOPHARM CORPORATION LIMITED | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Hsin Yang Liu
| Unternehmen | Position | Ende |
|---|---|---|
| REBER GENETICS CO LTD | Director/Board Member | - |
| BODY ORGAN BIOMEDICAL CORP | Director of Finance/CFO | - |
Ausbildung von Hsin Yang Liu
| National Taiwan University | Graduate Degree |
| Nankai University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TSH BIOPHARM CORPORATION LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Body Organ Biomedical Corp.
 Body Organ Biomedical Corp. BiotechnologyHealth Technology Body Organ Biomedical Corp. engages in the research, development, manufacture and sales of biomedical devices. It also provides regenerative solutions to restore tissue damage in orthopedics, dentistry, ophthalmology, reconstructive and general surgery. The company was founded on May 4, 2007 and is headquartered in Taipei, Taiwan. | Health Technology |
Reber Genetics Co., Ltd.
 Reber Genetics Co., Ltd. Pharmaceuticals: MajorHealth Technology Reber Genetics Co., Ltd. engages in the research, development, production, and sale of animal vaccines. Its products include PRRS and PCV2 subunit vaccines. The company was founded on April 18, 2008 and is headquartered in Taipei, Taiwan. | Health Technology |
